ROCKVILLE, Md.--(BUSINESS WIRE)--Celera (NYSE: CRA), an Applera Corporation business, today announced the publication of data from a research study validating its multi-gene Cirrhosis Risk Score (CRS) that predicts future risk of developing cirrhosis in patients with chronic hepatitis C (CHC). This paper is scheduled to appear in the August 2007 edition of Hepatology, published on behalf of the American Association for the Study of Liver Diseases, and is expected to be available on the publication’s website at www3.interscience.wiley.com/cgi-bin/jhome/106570044. The lead author of this paper was Hongjin Huang, Ph.D., Associate Director, Liver Diseases, at Celera.
